Alcon Launches New Dailies Colors Contact Lenses

Comments · 120 Views

Alcon Launches New Dailies Colors Contact Lenses

Alcon Launches New Dailies Colors Contact Lenses

Alcon officially announced the launch of new Dailies Colors contact lenses—daily disposable contact lenses that combine eye color enhancement with the convenience of a daily wear, according to a company news release. The new line features four colors—Mystic Blue, Mystic Gray, Mystic Hazel and Mystic Green—and is being introduced at a time when color contact lenses are re-emerging as an easy and creative way to express personal style. Dailies Colors are now available for purchase nationwide in a 30-count supply and will be available in a 90-count option later this year.To get more news about Yellow Contacts, you can visit official website.

As part of the launch, Alcon also announced its partnership with celebrity makeup artist Patrick Ta to create a collection of “Eye Styles,” signature looks inspired by the new Dailies Colors and existing AIR Optix Colors shades. The exclusive looks will debut monthly on the brand’s social media platforms throughout the remainder of the year, coinciding with key beauty-centric moments in time including Pride Month, festival season, back-to-school, Halloween and more.

The FDA on Thursday approved Soliris (eculizumab) injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. NMOSD is an autoimmune disease of the central nervous system that mainly affects the optic nerves and spinal cord.

“Soliris provides the first FDA-approved treatment for neuromyelitis optica spectrum disorder, a debilitating disease that profoundly impacts patients’ lives,” Billy Dunn, MD, director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research, said in an agency news release. “This approval changes the landscape of therapy for patients with NMOSD. Having an approved therapy for this condition is the culmination of extensive work we have engaged in with drug companies to expedite the development and approval of safe and effective treatments for patients with NMOSD, and we remain committed to these efforts for other rare diseases.”

In patients with NMOSD, the body’s immune system mistakenly attacks healthy cells and proteins in the body, most often in the optic nerves and spinal cord. Individuals with NMOSD typically have attacks of optic neuritis, which causes eye pain and vision loss. Individuals also can have attacks resulting in transverse myelitis, which often causes numbness, weakness, or paralysis of the arms and legs, along with loss of bladder and bowel control. Most attacks occur in clusters, days to months to years apart, followed by partial recovery during periods of remission. Approximately 50% of patients with NMOSD have permanent visual impairment and paralysis caused by NMOSD attacks. According to the National Institutes of Health, women are more often affected by NMOSD than men and African Americans are at greater risk of the disease than Caucasians. Estimates vary, but NMOSD is thought to impact approximately 4,000 to 8,000 patients in the United States.